Immunocore (NASDAQ:IMCR) Rating Reiterated by Needham & Company LLC

Immunocore (NASDAQ:IMCR)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a report released on Thursday, Benzinga reports. They presently have a $81.00 target price on the stock. Needham & Company LLC’s price target would suggest a potential upside of 43.29% from the company’s current price.

A number of other equities research analysts have also recently weighed in on IMCR. HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Immunocore in a research note on Wednesday, March 6th. Oppenheimer reiterated an “outperform” rating and issued a $87.00 price target (up from $85.00) on shares of Immunocore in a research report on Thursday, February 29th. JPMorgan Chase & Co. boosted their price target on shares of Immunocore from $60.00 to $70.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. Mizuho boosted their price target on shares of Immunocore from $86.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Finally, Canaccord Genuity Group boosted their price target on shares of Immunocore from $60.00 to $63.00 and gave the stock a “hold” rating in a research report on Thursday, February 29th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, Immunocore has a consensus rating of “Moderate Buy” and an average price target of $80.55.

Immunocore Stock Down 4.3 %

Shares of NASDAQ IMCR opened at $56.53 on Thursday. Immunocore has a fifty-two week low of $42.21 and a fifty-two week high of $76.98. The firm’s 50-day simple moving average is $65.75 and its 200 day simple moving average is $60.14. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.77 and a current ratio of 3.80.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.12). Immunocore had a negative net margin of 22.48% and a negative return on equity of 15.78%. The company had revenue of $70.16 million for the quarter, compared to the consensus estimate of $53.25 million. During the same quarter in the prior year, the firm earned ($0.63) earnings per share. Immunocore’s revenue for the quarter was up 22.4% compared to the same quarter last year. On average, equities research analysts predict that Immunocore will post -1.54 EPS for the current year.

Hedge Funds Weigh In On Immunocore

A number of institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. grew its stake in Immunocore by 103.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 836 shares of the company’s stock valued at $43,000 after acquiring an additional 426 shares in the last quarter. Wells Fargo & Company MN grew its stake in Immunocore by 89.7% during the 4th quarter. Wells Fargo & Company MN now owns 827 shares of the company’s stock valued at $47,000 after acquiring an additional 391 shares in the last quarter. Royal Bank of Canada purchased a new position in Immunocore during the 1st quarter valued at about $79,000. New York State Common Retirement Fund purchased a new position in Immunocore during the 1st quarter valued at about $98,000. Finally, IFP Advisors Inc grew its stake in Immunocore by 1,703.0% during the 2nd quarter. IFP Advisors Inc now owns 1,803 shares of the company’s stock valued at $108,000 after acquiring an additional 1,703 shares in the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.